Sagimet Biosciences Inc. Shares Surge on Positive Acne Treatment Trial Results
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company based in San Mateo, United States, experienced a significant surge in its stock price following the announcement of positive results from a Phase 3 trial of its acne treatment, Denifanstat. The company, which specializes in developing fatty acid synthase (FASN) inhibitors, saw its shares soar on June 4, 2025, as investors reacted to the promising trial outcomes.
The trial, conducted in partnership with Ascletis, demonstrated that Denifanstat, a first-in-class, once-daily oral FASN inhibitor, met all primary, key secondary, and secondary endpoints. The treatment showed statistically significant and clinically meaningful improvements compared to a placebo. Notably, Denifanstat was found to be 98% more effective than sarecycline, 178% more effective than doxycycline, and 60% more effective than clascoterone cream. Additionally, the treatment exhibited a favorable safety and tolerability profile.
The positive results were not limited to a single region. Sagimet’s partner achieved similar success in a Phase 3 trial conducted in China, where the acne therapy met its main goals. This international validation further bolstered investor confidence in the potential of Denifanstat as a groundbreaking treatment for moderate-to-severe acne.
As a result of these developments, Sagimet Biosciences’ stock price saw a notable increase. The company’s shares closed at $3.55 on May 29, 2025, with a 52-week high of $7.38 and a low of $1.73. The recent surge in stock price reflects the market’s optimistic outlook on the company’s future prospects, driven by the successful trial results.
Sagimet Biosciences Inc. continues to focus on developing novel therapeutics to address various health issues, including non-alcoholic steatohepatitis (NASH) and different types of cancer. With a market capitalization of $103,067,492 USD, the company remains a significant player in the health care sector, trading on the Nasdaq.
The positive trial results for Denifanstat mark a significant milestone for Sagimet Biosciences, positioning the company as a leader in the development of innovative acne treatments. As the company moves forward, it aims to leverage these successes to expand its global reach and continue its mission of improving patient outcomes through cutting-edge biopharmaceutical solutions.